Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1117
Abstract: This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D. read more here.
Keywords: medicare part; biosimilar products; utilization filgrastim; infliximab biosimilar ... See more keywords